Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Avril

Showing results (21-30 of 76) with videos related to

Pageof 8
Sort By:
Clinical Nuclear Medicine|July 19, 2005
FDG PET CT assessment of treatment response after yttrium-90 ibritumomab tiuxetan radioimmunotherapyJudith M Joyce, Berna Degirmenci, Samuel Jacobs, et al.
Seminars in Roentgenology|December 16, 2014
Whole-body positron emission tomography-magnetic resonance in breast cancerAndrew Sher, Laia Valls, Raymond F Muzic, et al.
Clinical Positron Imaging : Official Journal of the Institute for Clinical P.E.T|October 1, 2003
Utility of PET in Breast CancerNorbert Avril, Marcus Schelling, Jorg Dose, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|April 8, 2010
The clinical advances of fluorine-2-D-deoxyglucose--positron emission tomography/computed tomography in urological cancersNorbert Avril, Fatima Dambha, Iain Murray, et al.
Nuclear Medicine Communications|July 8, 2005
Whole-body PET/CT: spectrum of physiological variants, artifacts and interpretative pitfalls in cancer patientsLuis Gorospe, Subha Raman, Jon Echeveste, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 8, 2005
Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PETJoerg Dose Schwarz, Michael Bader, Lars Jenicke, et al.
Seminars in Roentgenology|December 16, 2014
Positron emission tomography/magnetic resonance imaging of the breastAndrew Sher, Jose L Vercher-Conejero, Raymond F Muzic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapySamuel A Jacobs, Nicholas Vidnovic, Judith Joyce, et al.
Seminars in Roentgenology|December 16, 2014
Early response monitoring of receptor tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma using [F-18]fluorothymidine-positron emission tomography-magnetic resonanceLaia Valls, Christopher Hoimes, Andrew Sher, et al.
Translational Oncology|April 17, 2016
Radiomics Analysis on FLT-PET/MRI for Characterization of Early Treatment Response in Renal Cell Carcinoma: A Proof-of-Concept StudyJacob Antunes, Satish Viswanath, Mirabela Rusu, et al.
Pageof 8

Showing results (21-30 of 76) with videos related to

Sort By:
Pageof 8
Clinical Nuclear Medicine|July 19, 2005
FDG PET CT assessment of treatment response after yttrium-90 ibritumomab tiuxetan radioimmunotherapyJudith M Joyce, Berna Degirmenci, Samuel Jacobs, et al.
Seminars in Roentgenology|December 16, 2014
Whole-body positron emission tomography-magnetic resonance in breast cancerAndrew Sher, Laia Valls, Raymond F Muzic, et al.
Clinical Positron Imaging : Official Journal of the Institute for Clinical P.E.T|October 1, 2003
Utility of PET in Breast CancerNorbert Avril, Marcus Schelling, Jorg Dose, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|April 8, 2010
The clinical advances of fluorine-2-D-deoxyglucose--positron emission tomography/computed tomography in urological cancersNorbert Avril, Fatima Dambha, Iain Murray, et al.
Nuclear Medicine Communications|July 8, 2005
Whole-body PET/CT: spectrum of physiological variants, artifacts and interpretative pitfalls in cancer patientsLuis Gorospe, Subha Raman, Jon Echeveste, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 8, 2005
Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PETJoerg Dose Schwarz, Michael Bader, Lars Jenicke, et al.
Seminars in Roentgenology|December 16, 2014
Positron emission tomography/magnetic resonance imaging of the breastAndrew Sher, Jose L Vercher-Conejero, Raymond F Muzic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapySamuel A Jacobs, Nicholas Vidnovic, Judith Joyce, et al.
Seminars in Roentgenology|December 16, 2014
Early response monitoring of receptor tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma using [F-18]fluorothymidine-positron emission tomography-magnetic resonanceLaia Valls, Christopher Hoimes, Andrew Sher, et al.
Translational Oncology|April 17, 2016
Radiomics Analysis on FLT-PET/MRI for Characterization of Early Treatment Response in Renal Cell Carcinoma: A Proof-of-Concept StudyJacob Antunes, Satish Viswanath, Mirabela Rusu, et al.
Pageof 8